AC Immune SA (ACIU) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed AC Immune SA (ACIU) over the past year, gaining 53.0% versus a loss of 27.6%. Over five years, ACIU leads with a -58.7% price change compared with -96.6% for ZNTL. Zentalis Pharmaceuticals is the larger company by market cap ($257.6 million vs $249.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | ZNTL |
|---|---|---|
| Share price | $2.51 | $2.63 |
| Market cap | $249.06M | $257.57M |
| 1-day change | -1.76% | +4.58% |
| YTD return | -18.79% | +85.93% |
| 1-year return | -27.56% | +53.05% |
| 5-year return | -58.74% | -96.65% |
| Forward P/E | 4.21 | — |
| EPS (TTM) | $-0.54 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $6.95 |
| 52-week low | $2.10 | $1.21 |
| Distance from 52-week high | -37.38% | -62.23% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +240.12% | +179.24% |
| Average volume | 201.86K | 1.21M |
| Shares outstanding | 99.43M | 98.12M |
| Employees | 90 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed ACIU by 80.6 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
ACIU vs ZNTL FAQ
Which is bigger, AC Immune SA or Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals (ZNTL) is larger, with a market capitalization of $257.57M compared with $249.06M for AC Immune SA (ACIU).
Which stock has performed better over the past year, ACIU or ZNTL?
ZNTL returned +53.05% over the past 12 months, compared with -27.56% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.